|
|
|
| Webinar: CAR-T Strategy in 2026: Scaling Autologous, Advancing Allogeneic | Explore what's next for CAR-T in this Thermo Fisher Scientific expert panel. As autologous therapies expand and allogeneic approaches advance, leaders discuss strategy across R&D, manufacturing, and commercialization. Gain insights into regulatory expectations, scalability, access, and supply chain models shaping CAR-T development in 2026 and beyond, highlighting challenges, opportunities, and priorities driving innovation across the evolving cell therapy landscape. Click here to learn more. |
|
|
|
|
By Gloria Lam, PA Consulting | Mainstream biopharma’s commercialization playbook isn’t working for cell and gene therapies. Orgs that invest in scalable platforms (and more) will see better success. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|